{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:38:51Z","timestamp":1778632731877,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T00:00:00Z","timestamp":1330905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T00:00:00Z","timestamp":1330905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2013,1,31]]},"DOI":"10.1038\/onc.2012.81","type":"journal-article","created":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T23:44:15Z","timestamp":1330991055000},"page":"599-609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8"],"prefix":"10.1038","volume":"32","author":[{"given":"W","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,5]]},"reference":[{"key":"BFonc201281_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38\u201351.","journal-title":"Nat Rev Cancer"},{"key":"BFonc201281_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/pros.20022","volume":"59","author":"K Halkidou","year":"2004","unstructured":"Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN . Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004; 59: 177\u2013189.","journal-title":"Prostate"},{"key":"BFonc201281_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1600-0463.2005.apm_04.x","volume":"113","author":"J Song","year":"2005","unstructured":"Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005; 113: 264\u2013268.","journal-title":"APMIS"},{"key":"BFonc201281_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","volume":"12","author":"BH Huang","year":"2005","unstructured":"Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1\/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005; 12: 395\u2013404.","journal-title":"Cell Death Differ"},{"key":"BFonc201281_CR5","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-05-0480","volume":"5","author":"A Hrzenjak","year":"2006","unstructured":"Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K et al. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 2006; 5: 2203\u20132210.","journal-title":"Mol Cancer Ther"},{"key":"BFonc201281_CR6","doi-asserted-by":"publisher","first-page":"28001","DOI":"10.1074\/jbc.272.44.28001","volume":"272","author":"WM Yang","year":"1997","unstructured":"Yang WM, Yao YL, Sun JM, Davie JR, Seto E . Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem 1997; 272: 28001\u201328007.","journal-title":"J Biol Chem"},{"key":"BFonc201281_CR7","doi-asserted-by":"publisher","first-page":"13548","DOI":"10.1074\/jbc.M510023200","volume":"281","author":"AJ Wilson","year":"2006","unstructured":"Wilson AJ, Byun DS, Popova N, Murray LB, L\u2019Italien K, Sowa Y et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006; 281: 13548\u201313558.","journal-title":"J Biol Chem"},{"key":"BFonc201281_CR8","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","volume":"16","author":"M Duvic","year":"2007","unstructured":"Duvic M, Vu J . Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16: 1111\u20131120.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFonc201281_CR9","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1158\/1078-0432.CCR-07-0162","volume":"13","author":"SS Ramalingam","year":"2007","unstructured":"Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007; 13: 3605\u20133610.","journal-title":"Clin Cancer Res"},{"key":"BFonc201281_CR10","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/bjc.2011.156","volume":"104","author":"PN Munster","year":"2011","unstructured":"Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011; 104: 1828\u20131835.","journal-title":"Br J Cancer"},{"key":"BFonc201281_CR11","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","volume":"29","author":"M Kirschbaum","year":"2011","unstructured":"Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 1198\u20131203.","journal-title":"J Clin Oncol"},{"key":"BFonc201281_CR12","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.str.2004.04.012","volume":"12","author":"JR Somoza","year":"2004","unstructured":"Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004; 12: 1325\u20131334.","journal-title":"Structure"},{"key":"BFonc201281_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0962-8924(99)01536-6","volume":"9","author":"DE Ayer","year":"1999","unstructured":"Ayer DE . Histone deacetylases: transcriptional repression with SINers and NuRDs. Trends Cell Biol 1999; 9: 193\u2013198.","journal-title":"Trends Cell Biol"},{"key":"BFonc201281_CR14","doi-asserted-by":"publisher","first-page":"23658","DOI":"10.1074\/jbc.M203690200","volume":"277","author":"G David","year":"2002","unstructured":"David G, Neptune MA, DePinho RA . SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities. J Biol Chem 2002; 277: 23658\u201323663.","journal-title":"J Biol Chem"},{"key":"BFonc201281_CR15","doi-asserted-by":"publisher","first-page":"31826","DOI":"10.1074\/jbc.M204149200","volume":"277","author":"SC Tsai","year":"2002","unstructured":"Tsai SC, Seto E . Regulation of histone deacetylase 2 by protein kinase CK2. J Biol Chem 2002; 277: 31826\u201331833.","journal-title":"J Biol Chem"},{"key":"BFonc201281_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/jcb.20179","volume":"93","author":"N Sengupta","year":"2004","unstructured":"Sengupta N, Seto E . Regulation of histone deacetylase activities. J Cell Biochem 2004; 93: 57\u201367.","journal-title":"J Cell Biochem"},{"key":"BFonc201281_CR17","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1128\/MCB.24.2.765-773.2004","volume":"24","author":"H Lee","year":"2004","unstructured":"Lee H, Rezai-Zadeh N, Seto E . Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol 2004; 24: 765\u2013773.","journal-title":"Mol Cell Biol"},{"key":"BFonc201281_CR18","doi-asserted-by":"publisher","first-page":"15254","DOI":"10.1074\/jbc.M908988199","volume":"275","author":"E Hu","year":"2000","unstructured":"Hu E, Chen Z, Fredrickson T, Zhu Y, Kirkpatrick R, Zhang GF et al. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem 2000; 275: 15254\u201315264.","journal-title":"J Biol Chem"},{"key":"BFonc201281_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1078-0432.CCR-08-0684","volume":"15","author":"I Oehme","year":"2009","unstructured":"Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009; 15: 91\u201399.","journal-title":"Clin Cancer Res"},{"key":"BFonc201281_CR20","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1016\/j.bmcl.2007.02.064","volume":"17","author":"K Krennhrubec","year":"2007","unstructured":"Krennhrubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM . Design and evaluation of \u2018Linkerless\u2019 hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007; 17: 2874\u20132878.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFonc201281_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1006\/scbi.1998.0094","volume":"8","author":"D Reisman","year":"1998","unstructured":"Reisman D, Loging WT . Transcriptional regulation of the p53 tumor suppressor gene. Semin Cancer Biol 1998; 8: 317\u2013324.","journal-title":"Semin Cancer Biol"},{"key":"BFonc201281_CR22","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/35016125","volume":"405","author":"V Raman","year":"2000","unstructured":"Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, Jaffee E et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 2000; 405: 974\u2013978.","journal-title":"Nature"},{"key":"BFonc201281_CR23","doi-asserted-by":"publisher","first-page":"6982","DOI":"10.1158\/0008-5472.CAN-06-0511","volume":"66","author":"S Wang","year":"2006","unstructured":"Wang S, El-Deiry WS . p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res 2006; 66: 6982\u20136989.","journal-title":"Cancer Res"},{"key":"BFonc201281_CR24","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1101\/gad.1662908","volume":"22","author":"T Terzian","year":"2008","unstructured":"Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008; 22: 1337\u20131344.","journal-title":"Genes Dev"},{"key":"BFonc201281_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","volume":"363","author":"MA Glozak","year":"2005","unstructured":"Glozak MA, Sengupta N, Zhang X, Seto E . Acetylation and deacetylation of non-histone proteins. Gene 2005; 363: 15\u201323.","journal-title":"Gene"},{"key":"BFonc201281_CR26","doi-asserted-by":"publisher","first-page":"20436","DOI":"10.1074\/jbc.M000202200","volume":"275","author":"LJ Juan","year":"2000","unstructured":"Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000; 275: 20436\u201320443.","journal-title":"J Biol Chem"},{"key":"BFonc201281_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/35042612","volume":"408","author":"J Luo","year":"2000","unstructured":"Luo J, Su F, Chen D, Shiloh A, Gu W . Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000; 408: 377\u2013381.","journal-title":"Nature"},{"key":"BFonc201281_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0092-8674(01)00527-X","volume":"107","author":"H Vaziri","year":"2001","unstructured":"Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149\u2013159.","journal-title":"Cell"},{"key":"BFonc201281_CR29","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-06-4397","volume":"67","author":"KL Harms","year":"2007","unstructured":"Harms KL, Chen X . Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 2007; 67: 3145\u20133152.","journal-title":"Cancer Res"},{"key":"BFonc201281_CR30","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/cdd.2011.71","volume":"18","author":"D Li","year":"2011","unstructured":"Li D, Marchenko ND, Moll UM . SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 2011; 18: 1904\u20131913.","journal-title":"Cell Death Differ"},{"key":"BFonc201281_CR31","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1073\/pnas.0307708100","volume":"101","author":"CY Gui","year":"2004","unstructured":"Gui CY, Ngo L, Xu WS, Richon VM, Marks PA . Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101: 1241\u20131246.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc201281_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","volume":"277","author":"O Witt","year":"2009","unstructured":"Witt O, Deubzer HE, Milde T, Oehme I . HDAC family: what are the cancer relevant targets? Cancer Lett 2009; 277: 8\u201321.","journal-title":"Cancer Lett"},{"key":"BFonc201281_CR33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1042\/BJ20070779","volume":"409","author":"N Khan","year":"2008","unstructured":"Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008; 409: 581\u2013589.","journal-title":"Biochem J"},{"key":"BFonc201281_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00280-010-1324-y","volume":"66","author":"N Noureen","year":"2010","unstructured":"Noureen N, Rashid H, Kalsoom S . Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Cancer Chemother Pharmacol 2010; 66: 625\u2013633.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFonc201281_CR35","doi-asserted-by":"publisher","first-page":"2485S","DOI":"10.1093\/jn\/133.7.2485S","volume":"133","author":"JR Davie","year":"2003","unstructured":"Davie JR . Inhibition of histone deacetylase activity by butyrate. J Nutr 2003; 133: 2485S\u20132493S.","journal-title":"J Nutr"},{"key":"BFonc201281_CR36","first-page":"166","volume":"3","author":"HJ Kim","year":"2011","unstructured":"Kim HJ, Bae SC . Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011; 3: 166\u2013179.","journal-title":"Am J Transl Res"},{"key":"BFonc201281_CR37","doi-asserted-by":"publisher","first-page":"F293","DOI":"10.1152\/ajprenal.00410.2009","volume":"298","author":"G Dong","year":"2010","unstructured":"Dong G, Luo J, Kumar V, Dong Z . Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. Am J Physiol Renal Physiol 2010; 298: F293\u2013F300.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFonc201281_CR38","doi-asserted-by":"publisher","first-page":"13554","DOI":"10.1021\/bi801610c","volume":"47","author":"DP Dowling","year":"2008","unstructured":"Dowling DP, Gantt SL, Gattis SG, Fierke CA, Christianson DW . Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. Biochemistry 2008; 47: 13554\u201313563.","journal-title":"Biochemistry"},{"key":"BFonc201281_CR39","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","volume":"45","author":"P Bertrand","year":"2010","unstructured":"Bertrand P . Inside HDAC with HDAC inhibitors. Eur J Med Chem 2010; 45: 2095\u20132116.","journal-title":"Eur J Med Chem"},{"key":"BFonc201281_CR40","doi-asserted-by":"publisher","first-page":"19373","DOI":"10.1074\/jbc.M413528200","volume":"280","author":"H Chen","year":"2005","unstructured":"Chen H, Rubin E, Zhang H, Chung S, Jie CC, Garrett E et al. Identification of transcriptional targets of HOXA5. J Biol Chem 2005; 280: 19373\u201319380.","journal-title":"J Biol Chem"},{"key":"BFonc201281_CR41","doi-asserted-by":"publisher","first-page":"12178","DOI":"10.1074\/jbc.M900994200","volume":"284","author":"W Yan","year":"2009","unstructured":"Yan W, Chen X . Identification of GRO1 as a critical determinant for mutant p53 gain of function. J Biol Chem 2009; 284: 12178\u201312187.","journal-title":"J Biol Chem"},{"key":"BFonc201281_CR42","doi-asserted-by":"publisher","first-page":"14229","DOI":"10.1074\/jbc.M109.097253","volume":"285","author":"W Yan","year":"2010","unstructured":"Yan W, Chen X . Characterization of functional domains necessary for mutant p53 gain of function. J Biol Chem 2010; 285: 14229\u201314238.","journal-title":"J Biol Chem"},{"key":"BFonc201281_CR43","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/jcb.22185","volume":"107","author":"PA Marks","year":"2009","unstructured":"Marks PA, Xu WS . Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009; 107: 600\u2013608.","journal-title":"J Cell Biochem"},{"key":"BFonc201281_CR44","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1158\/1078-0432.CCR-08-2784","volume":"15","author":"MT McCabe","year":"2009","unstructured":"McCabe MT, Brandes JC, Vertino PM . Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 2009; 15: 3927\u20133937.","journal-title":"Clin Cancer Res"},{"key":"BFonc201281_CR45","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S0959-8049(03)00072-8","volume":"39","author":"AE Chambers","year":"2003","unstructured":"Chambers AE, Banerjee S, Chaplin T, Dunne J, Debernardi S, Joel SP et al. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 2003; 39: 1165\u20131175.","journal-title":"Eur J Cancer"},{"key":"BFonc201281_CR46","first-page":"151","volume":"2","author":"KB Glaser","year":"2003","unstructured":"Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK . Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2: 151\u2013163.","journal-title":"Mol Cancer Ther"},{"key":"BFonc201281_CR47","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1073\/pnas.2536759100","volume":"101","author":"CS Mitsiades","year":"2004","unstructured":"Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004; 101: 540\u2013545.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc201281_CR48","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1073\/pnas.0500369102","volume":"102","author":"MJ Peart","year":"2005","unstructured":"Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 3697\u20133702.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc201281_CR49","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.bcp.2004.11.008","volume":"69","author":"Y Sasakawa","year":"2005","unstructured":"Sasakawa Y, Naoe Y, Sogo N, Inoue T, Sasakawa T, Matsuo M et al. Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 2005; 69: 603\u2013616.","journal-title":"Biochem Pharmacol"},{"key":"BFonc201281_CR50","doi-asserted-by":"publisher","first-page":"10833","DOI":"10.1073\/pnas.191208598","volume":"98","author":"AA Ruefli","year":"2001","unstructured":"Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833\u201310838.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc201281_CR51","first-page":"4460","volume":"63","author":"MJ Peart","year":"2003","unstructured":"Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O\u2019Reilly LA et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63: 4460\u20134471.","journal-title":"Cancer Res"},{"key":"BFonc201281_CR52","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/leu.2008.9","volume":"22","author":"S Balasubramanian","year":"2008","unstructured":"Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ . A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008; 22: 1026\u20131034.","journal-title":"Leukemia"},{"key":"BFonc201281_CR53","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1128\/MCB.25.5.2014-2030.2005","volume":"25","author":"KL Harms","year":"2005","unstructured":"Harms KL, Chen X . The C terminus of p53 family proteins is a cell fate determinant. Mol Cell Biol 2005; 25: 2014\u20132030.","journal-title":"Mol Cell Biol"},{"key":"BFonc201281_CR54","doi-asserted-by":"publisher","first-page":"17557","DOI":"10.1074\/jbc.M210696200","volume":"278","author":"G Liu","year":"2003","unstructured":"Liu G, Xia T, Chen X . The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300\/CREB-binding protein. J Biol Chem 2003; 278: 17557\u201317565.","journal-title":"J Biol Chem"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc201281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc201281","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc201281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T19:38:31Z","timestamp":1647891511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc201281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,1,31]]}},"alternative-id":["BFonc201281"],"URL":"https:\/\/doi.org\/10.1038\/onc.2012.81","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,5]]},"assertion":[{"value":"13 October 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}